Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging…
NOVO NORDISK $NVO SAYS WEGOVY PILL HAS PASSED 8 MILLION US PRESCRIPTIONS SINCE ITS JANUARY LAUNCH Novo calls it the strongest-ever GLP-1 volume launch in the US. The pill drew about 3.6 million prescriptions in Q3 alone, not far behind the roughly 4.1 million for Wegovy…
Busy morning ahead. Midterms reaction. ADP jobs report. ISM services. Earnings from $MCD $NVO $UBER $CVS.
EARNINGS SEASON IS NOT DONE Here is a look at some of the largest earnings we have coming up during November from our sponsors over at Bitget Tradfi Nov 2: Apple $AAPL, Palantir $PLTR Nov 3: AMD $AMD Nov 4: Arm $ARM, Qualcomm $QCOM, McDonald's $MCD, Novo Nordisk $NVO Nov 5:…
Big earnings week: November 2, 2026 https://t.co/twAkSIUblW via @MarketAtlas @BearBullTraders $AAPL $PLTR $AMD $SHOP $MRNA $SMCI $TXG $UBER $LITE $COHR $DIBS $APP $AEHR $QCOM $AMC $CAVA $RIOT $BKNG $TEAM $NVO $ABNB $ETN $BXSL $MPC $FN $GFS $DDOG $MP $U $IREN $FISV $BROS $RUN…
Earnings galore too. $AAPL $PLTR $VRTX $MAR $ON $FOXA $ROKU $AMD $AMGN $SHOP $PFE $ETN $BKNG $RACE $APO $KDP $XYZ $YUM $SYY $ARM $QCOM $NVO $MCD $UBER $CVS $MCK $DDOG $APP $ALL $MET $AFL $CRCL Barron's/Dow Jones owner $NWSA $COP $SONY $MNST $ABNB $LITE $MRNA $HUM $VST + many more
Obesity landscape The market is telling the story. If Novo Nordisk's obesity franchise were truly on par with Eli Lilly's, $NVO would be making new highs rather than struggling. Based on the clinical data to date, $VKTX remains the only obvious challenger to Lilly's obesity
14 analysts rate NVO Hold on consensus.
Consensus price target: $45.05 (+12.09% upside from $40.19)
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $46.56B | +6.43% | $15.43B |
| 2024 | $43.75B | +25.03% | $15.21B |
| 2023 | $34.99B | +31.26% | $12.61B |
Stock data for NVO: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics